| Page 12 | Kisaco Research
 

Bryan Goodman

Executive Director, AI
Ford

Bryan Goodman is the Executive Director of Artificial Intelligence in Ford’s data and analytics organization. He focuses on enabling the use of AI throughout Ford. This includes coordinating infrastructure, tools, and training, and developing advanced AI applications. He chairs Ford's AI technology and ethics council. He is an inventor on 13 US patents.  Bryan received his PhD in physical chemistry and computational science and engineering from the University of Illinois.

Read full bio

Bryan Goodman

Executive Director, AI
Ford

Bryan Goodman

Executive Director, AI
Ford

Bryan Goodman is the Executive Director of Artificial Intelligence in Ford’s data and analytics organization. He focuses on enabling the use of AI throughout Ford. This includes coordinating infrastructure, tools, and training, and developing advanced AI applications. He chairs Ford's AI technology and ethics council. He is an inventor on 13 US patents.  Bryan received his PhD in physical chemistry and computational science and engineering from the University of Illinois.

 

Denise Keeler

Chief Growth Officer
OrangeTwist

Denise Keeler

Chief Growth Officer
OrangeTwist

Denise Keeler

Chief Growth Officer
OrangeTwist

Part I: Managing Career Progression, Establishing Influence and Leading Effective Teams in the Life Science Legal Sector

This quickfire presentation will examine how influence is built and exercised within life science legal functions, and how it shapes decision-making authority, career trajectory and team performance.

Part II: Building Strategic Influence as Women in Life Sciences Legal Leadership

This session will bring together senior in-house counsel and private practitioners for a candid discussion on career progression, leadership development and building influence within life science organisations. Participants will exchange practical perspectives on navigating leadership transitions, building internal visibility and positioning themselves for senior roles across the legal function. The session will be structured to encourage peer-to-peer discussion, allowing attendees to share experiences and practical strategies across IP, regulatory, competition and corporate legal disciplines.

Author:

Jamie Pearson

General Counsel & Chief Compliance Officer
Shionogi Europe
... read more

Jamie Pearson

General Counsel & Chief Compliance Officer
Shionogi Europe

Author:

Fleur Herrenschmidt

Chief Legal Officer
Norgine
... read more

Fleur Herrenschmidt

Chief Legal Officer
Norgine

Author:

Laila Beynon

Director, Dispute Resolution
Regeneron

Laila Beynon is Director, Dispute Resolution at Regeneron, responsible for the strategic co-ordination of ex-US patent litigation. She has a PhD in Biochemistry/Molecular Biology, 10 years’ private practice experience in life sciences patent litigation at Herbert Smith Freehills LLP, and prior to her role at Regeneron headed up the Patent Litigation team at BAT. 

... read more

Laila Beynon

Director, Dispute Resolution
Regeneron

Laila Beynon is Director, Dispute Resolution at Regeneron, responsible for the strategic co-ordination of ex-US patent litigation. She has a PhD in Biochemistry/Molecular Biology, 10 years’ private practice experience in life sciences patent litigation at Herbert Smith Freehills LLP, and prior to her role at Regeneron headed up the Patent Litigation team at BAT. 

Author:

Lena Moran-Adams

Group General Counsel
-
... read more

Lena Moran-Adams

Group General Counsel
-

Author:

Veronika Hughes-Bednar

VP, Global Head of Legal Transactions
Astellas Pharma
... read more

Veronika Hughes-Bednar

VP, Global Head of Legal Transactions
Astellas Pharma

This interactive discussion explores how knowing what evidence and arguments have already succeeded or failed in litigation/oppositions around the world provides a head start and advantage in preparing or defending cases at the EPO and courts. 

Author:

Alex Eichner

Senior Director Legal & Regulatory Europe
IPD Analytics

Alexander Eichner is a Senior Director of European Legal & Regulatory Analysis at IPD Analytics. He observes, analyses, and predicts EPO oppositions and appeals, national court proceedings, and UPC hearings, and coordinates IPD’s coverage of these disputes across Europe and globally. He also analyses IP portfolios in the pharmaceutical, biotech, and medtech sectors and contributes to the development of new legal and insights products.

Before joining IPD Analytics in 2021, he spent seven years at top-tier Munich patent law firms specializing in biotechnology. He is a qualified European and German Patent Attorney and a registered UPC Representative. He holds a BSc and MSc in Biochemistry from the Technical University of Munich and a doctorate based on research conducted at the Institute of Science and Technology Austria.

... read more

Alex Eichner

Senior Director Legal & Regulatory Europe
IPD Analytics

Alexander Eichner is a Senior Director of European Legal & Regulatory Analysis at IPD Analytics. He observes, analyses, and predicts EPO oppositions and appeals, national court proceedings, and UPC hearings, and coordinates IPD’s coverage of these disputes across Europe and globally. He also analyses IP portfolios in the pharmaceutical, biotech, and medtech sectors and contributes to the development of new legal and insights products.

Before joining IPD Analytics in 2021, he spent seven years at top-tier Munich patent law firms specializing in biotechnology. He is a qualified European and German Patent Attorney and a registered UPC Representative. He holds a BSc and MSc in Biochemistry from the Technical University of Munich and a doctorate based on research conducted at the Institute of Science and Technology Austria.

Author:

Florian Brandt

Senior Director Legal & Regulatory Europe
IPD Analytics

Florian Brandt is a Senior Director on IPD Analytics' European Legal & Regulatory team. He is a qualified European and German Patent Attorney and a registered UPC Representative. At IPD, he works on legal analyses of key decisive patent validity and infringement litigation with the most significant potential market impact on small and large molecule pharmaceutical products across all major European venues. Florian is also involved in developing IPD’s tracking, analytics, and insights solutions.

Before joining IPD in 2018, Florian worked at a top-tier patent law firm in Germany in prosecution and litigation of life science patent portfolios covering both small and large molecule products (2010-2018). He holds science degrees in Biochemistry from the Technical University of Munich and a PhD for studies at the Max-Planck Institute of Biochemistry. 

... read more

Florian Brandt

Senior Director Legal & Regulatory Europe
IPD Analytics

Florian Brandt is a Senior Director on IPD Analytics' European Legal & Regulatory team. He is a qualified European and German Patent Attorney and a registered UPC Representative. At IPD, he works on legal analyses of key decisive patent validity and infringement litigation with the most significant potential market impact on small and large molecule pharmaceutical products across all major European venues. Florian is also involved in developing IPD’s tracking, analytics, and insights solutions.

Before joining IPD in 2018, Florian worked at a top-tier patent law firm in Germany in prosecution and litigation of life science patent portfolios covering both small and large molecule products (2010-2018). He holds science degrees in Biochemistry from the Technical University of Munich and a PhD for studies at the Max-Planck Institute of Biochemistry. 

Author:

Joshua Bleet

Executive VP of International Legal & Regulatory Analysis
IPD Analytics

Joshua Bleet is the Executive Vice President of International Legal & Regulatory Analysis at IPD Analytics. Joshua joined IPD 17 years ago after working as a patent litigator and clerking for Judge Alvin A. Schall of the U.S. Court of Appeals for the Federal Circuit. He leads a team of attorneys who observe, analyze, and predict court and patent office proceedings in Europe (EPO, national courts, UPC), Japan, China, India, Canada, Australia, Korea, Brazil, Russia, Mexico, and Taiwan). He also leads teams dedicated to Global Litigation Tracking, Expert Witness Insights, Settlement Analytics, and Claim Construction Insights.  Previously, Joshua led IPD’s development of the European Supplementary Protection Certificate Tracker. His favorite part of the job is solving problems thought to be unsolvable.

... read more

Joshua Bleet

Executive VP of International Legal & Regulatory Analysis
IPD Analytics

Joshua Bleet is the Executive Vice President of International Legal & Regulatory Analysis at IPD Analytics. Joshua joined IPD 17 years ago after working as a patent litigator and clerking for Judge Alvin A. Schall of the U.S. Court of Appeals for the Federal Circuit. He leads a team of attorneys who observe, analyze, and predict court and patent office proceedings in Europe (EPO, national courts, UPC), Japan, China, India, Canada, Australia, Korea, Brazil, Russia, Mexico, and Taiwan). He also leads teams dedicated to Global Litigation Tracking, Expert Witness Insights, Settlement Analytics, and Claim Construction Insights.  Previously, Joshua led IPD’s development of the European Supplementary Protection Certificate Tracker. His favorite part of the job is solving problems thought to be unsolvable.

 

Radhika Malik

Partner
Dell Technologies Capital

At DTC, Radhika invests across the enterprise stack focusing on AI/ML, cloud infrastructure and deep tech.

Read full bio

Radhika Malik

Partner
Dell Technologies Capital

Radhika Malik

Partner
Dell Technologies Capital

At DTC, Radhika invests across the enterprise stack focusing on AI/ML, cloud infrastructure and deep tech. When considering a new investment, she looks for deeply technical founders who want to solve impactful problems, while also forming a long-lasting relationship. She appreciates DTC’s collaborative style, focused domain expertise, company building experience and access to the Dell ecosystem.

Before DTC, Radhika was an investor with Samsung Catalyst Fund, Samsung’s deep technology venture fund covering AI/ML, semiconductors, cloud, data and 5G. Prior to becoming an investor, she worked as a software engineer and product manager at early-stage startups including Panorama Education and MindMeld (acq. by Cisco), as well as large corporations including Microsoft and Amazon. Transitioning from technical lead to investor, Radhika was a venture capital fellow at Glasswing Ventures and then with The Yard Ventures.

Radhika supports several efforts that aim to boost the number of women in technical and investing roles. She’s an active member of the groups All Raise and Women in VC. She’s also held volunteer and mentorship roles with Women Who Code, Girls Who Code, and Code for Boston. She holds a B.S. and M.Eng. from MIT in Computer Science and an MBA from Harvard Business School.

Current Companies
 

Alex Potlog

Senior Counsel, Global Legal Strategies & Policy
AbbVie

Alex Potlog

Senior Counsel, Global Legal Strategies & Policy
AbbVie

Alex Potlog

Senior Counsel, Global Legal Strategies & Policy
AbbVie
 

Ruth Cotter

Chief Administrative Officer
AMD

Ruth Cotter is Senior Vice President and Chief Administrative Officer at AMD, leading the company’s integrated and enterprise-wide Corporate Operations Group. She oversees Marketing, Communications, Human Resources, Corporate Security, Information Technology, and Indirect Procurement. With more than 25 years of experience, Cotter’s leadership has been instrumental in helping the company scale during hypergrowth and is guided by thoughtful policy, strategic planning and leadership.

 

Read full bio

Ruth Cotter

Chief Administrative Officer
AMD

Ruth Cotter

Chief Administrative Officer
AMD

Ruth Cotter is Senior Vice President and Chief Administrative Officer at AMD, leading the company’s integrated and enterprise-wide Corporate Operations Group. She oversees Marketing, Communications, Human Resources, Corporate Security, Information Technology, and Indirect Procurement. With more than 25 years of experience, Cotter’s leadership has been instrumental in helping the company scale during hypergrowth and is guided by thoughtful policy, strategic planning and leadership.

 

Under her leadership, the marketing team significantly increased AMD brand awareness through its “together we advance” brand, strengthened thought leadership positioning of AMD Executive Team and increased engagement and commitment among AMD’s 28,000+ employees. She has led the HR team during a period when AMD doubled the size of its workforce with a strong focus on belonging and inclusion through improved company policies, benefits and community engagement.

 

Cotter also leads the AMD Integration Planning Office for the ZT Systems acquisition, which plays an essential role in coordinating and facilitating integration. In her previous role, she oversaw the integration of the Xilinx acquisition, the largest semiconductor transaction of its time, and investor relations, where she led a proactive investor outreach campaign that resulted in AMD being among the best-performing stocks on the S&P 500.

 

Cotter is Executive Sponsor of the Women’s Forum and AMD PRIDE Employee Resource Groups. She serves on the Global Semiconductor Alliance (GSA) Women’s Leadership Council and was named to the PRWeek US Power List in 2024. She has previously received recognition in Technology Magazine's Top 100 Women in Technology, the National Diversity Council’s Top 50 Most Powerful Women in Tech and Top 100 HR and Communication Professionals.

AI is rapidly transforming life sciences and healthcare, powering applications in drug development, diagnostics and clinical decision support. With many technologies now likely to fall within the EU AI Act’s high-risk category, companies must implement robust governance and oversight mechanisms while navigating complex interactions with medical device frameworks and emerging product liability rules.

This session will examine how the EU AI Act’s high risk framework is shaping AI deployment across the industry, and explore the implications of the landmark legislation for your legal governance structures, technology validation and liability risk.

-Which life science technologies are most likely to fall within the EU AI Act’s high-risk classification?
- What governance, transparency and human oversight obligations will companies need to implement when deploying high-risk AI systems?
- How will the AI Act interact with existing MDR and IVDR frameworks, particularly for AI-enabled diagnostics and medical device software?
- Could overlapping requirements between the AI Act, MDR/IVDR and product liability frameworks create new litigation risks and challenges for technology validation?
- What practical steps should legal teams take to ensure their high-risk AI governance frameworks are fit for purpose?

Author:

Cornelia Keller

VP & General Counsel
Merz Therapeutics
... read more

Cornelia Keller

VP & General Counsel
Merz Therapeutics

Author:

Ianina Liebold

Senior Director Legal
BioNTech
... read more

Ianina Liebold

Senior Director Legal
BioNTech

Author:

Pascal Hofer

Head of Legal Digital & IT
Roche
... read more

Pascal Hofer

Head of Legal Digital & IT
Roche